Bcl-2／IgH和IgH基因重排与非霍奇金淋巴瘤诊断和化疗效果的相关性研究  

The study of relationship between Bcl-2/IgH,IgH gene rearrangement and the diagnosis and chemotherapy effect of B-NHL

作　　者：施姗姗[1] 胡长路[1] 余元勋 李娟[3] 

机构地区：[1]合肥安徽医科大学附属省立医院肿瘤科230000 [2]安徽省遗传中心230000 [3]合肥市第一人民医院肿瘤科230000

出　　处：《临床肿瘤学杂志》2009年第1期55-58,共4页Chinese Clinical Oncology

摘　　要：目的:通过对Bcl-2/IgH及IgH基因重排的联合检测,探讨两种标志物与B细胞型非霍奇金淋巴瘤(B-NHL)诊断与疗效的相关性。方法:对49例初治的B-NHL患者采用以CHOP方案为基础的化疗,在化疗前及化疗后6周期时以PCR一步法进行上述指标的检测。结果:化疗前49例患者的Bcl-2/IgH和IgH基因重排联合检测率达到91.8%,治疗后达到CR的21例病例中,4例IgH基因重排转阴,2例Bcl-2/IgH转阴。结论:Bcl-2/IgH联合IgH基因重排检测作为分子学标志物比单纯采用Bcl-2/IgH或是单纯IgH重排更为敏感,但是取得CR的病例中,Bcl-2/IgH和IgH基因重排在化疗前后无明显变化,提示短期内对于临床CR的患者,上述指标不能做为适时的分子学指标。To observed the Bcl-2/IgH and IgH gene rearrangement in order to improve the positive ratio of molecular diagnosis and know the relationship with chemotherapy effect. Methods：The polymerase chain reaction was used to test the Bcl-2/ IgH, lgH gene rearrangement of 49 B-NHL patients who are accepted the first therapy. Results：The ratio of the combined detection was 91.8% , and there are 4 cases the IgH gene rearrangement darkened and 2 cases Bcl-2/IgH rearrangement darkened in the 21 cases undergoing the therapy who get to complete relieve. Conclusion：The combined detection is more sensitive than the single marker. There is no apparent changing in the cases which comes to the complete relieve, and the numerator marker is not adapted to as the grant marker in the short time to response the prognosis for the patients who get to complete relieve.

关 键 词：非霍奇金淋巴瘤 BCL-2/IGH IgH 基因重排 诊断 

分 类 号：R733.1[医药卫生—肿瘤]